Summit Therapeutics Inc. Quarterly Deferred Tax Assets, Valuation Allowance in USD from Q4 2017 to Q4 2023

Taxonomy & unit
us-gaap: USD
Description
Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.
Summary
Summit Therapeutics Inc. quarterly Deferred Tax Assets, Valuation Allowance history and growth rate from Q4 2017 to Q4 2023.
  • Summit Therapeutics Inc. Deferred Tax Assets, Valuation Allowance for the quarter ending December 31, 2023 was $84.8M, a 32.4% increase year-over-year.
Deferred Tax Assets, Valuation Allowance, Quarterly (USD)
Deferred Tax Assets, Valuation Allowance, YoY Quarterly Growth (%)
Period Value YoY Chg Change % Date Report Filed
Q4 2023 $84.8M +$20.7M +32.4% Dec 31, 2023 10-K 2024-02-20
Q4 2022 $64M +$12.3M +23.7% Dec 31, 2022 10-K 2024-02-20
Q4 2021 $51.7M +$22.5M +77% Dec 31, 2021 10-K 2024-02-20
Q4 2020 $29.2M +$10.8M +58.9% Dec 31, 2020 10-K/A 2022-12-21
Q4 2019 $18.4M +$1.8M +10.8% Dec 31, 2019 10-K 2021-03-31
Q4 2018 $16.6M -$1.69M -9.23% Jan 31, 2019 8-K 2020-09-29
Q4 2017 $18.3M Jan 31, 2018 8-K 2020-09-29
* An asterisk sign (*) next to the value indicates that the value is likely invalid.